ClinicalTrials.gg
CompletedNCT00110591Updated Mar 14, 2023Results posted

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

A Phase 1 interventional study of PRO 140 in HIV Infections, sponsored by CytoDyn, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-14.

Sponsored by CytoDyn, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.

Enrollment
1,807th of 2,150
20 · median 60
Started
2004
with 106 others
Phase 1
671 of 2,802
10 open now
Registered
1,406th of 2,802
by date

Among the 2,802 studies in HIV Infections with a site in United States, this one is the 1,807th largest by enrollment of the 2,150 interventional ones that give a count, is one of 107 that started in 2004, is one of 671 in phase 1, and was the 1,406th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

83 of the 2,802 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,802 studies in HIV Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine the safety and tolerability of PRO 140, an investigational anti-HIV drug, administered via intravenous infusion.

Study hypothesis: Single intravenous doses of PRO 140 can be safely administered to humans and will result in measurable concentrations of the product in serum.

Read the detailed description

PRO 140 is a man-made monoclonal antibody to the chemokine receptor CCR5, which serves as a co-receptor for HIV. In numerous preclinical models of HIV infection, PRO 140 broadly and potently blocks CCR5-mediated HIV entry without blocking the natural activity of CCR5. PRO 140 is being developed for therapy of HIV infected individuals. The purpose of this study is to evaluate the safety and tolerability of PRO 140 in HIV uninfected male volunteers. The pharmacokinetics and pharmacodynamics of PRO 140 will also be assessed in this study.

Participants in this study will be randomly assigned to receive a single dose of one of several possible doses of PRO 140 or placebo. Participants will remain in the clinic for observation and evaluation for 24 hours after the single-dose administration. Follow-up visits will occur at 2, 3, 5, 7, 10, 14, 28, 42, and 60 days post-treatment. Physical exams, electrocardiograms (ECGs), vital signs measurement, adverse event reporting, and blood and urine collection will occur at most visits.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Not more than 20% below or 20% above ideal weight for height and estimated frame size
  • Good health, with no abnormal findings on the physical examination, medical history, or laboratory tests

Exclusion criteria

Exclusion Criteria:

  • History of disease
  • History of clinically significant allergies, including drug allergy
  • Participated in another clinical trial within the 3 months prior to study entry
  • infected
  • or C virus infected
  • Active significant infection
  • Prior exposure, allergy, or known to PRO 140
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Intravenous placebo for PRO 140

    Drug: PRO 140

  • Experimental
    PRO 140 dose 1

    0.1 mg/kg PRO 140 by intravenous infusion

    Drug: PRO 140

  • Experimental
    PRO 140 dose 2

    0.5 mg/kg PRO 140 by intravenous infusion

    Drug: PRO 140

  • Experimental
    PRO 140 dose 3

    2.0 mg/kg PRO 140 by intravenous infusion

    Drug: PRO 140

  • Experimental
    PRO 140 dose 4

    5.0 mg/kg PRO 140 by intravenous infusion

    Drug: PRO 140

Interventions

  • Monoclonal antibody to CCR5

    Also known as: Humanized monoclonal antibody to CCR5

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of PRO 140

    Time frame: 60 days

07

Results

Posted Mar 14, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboPRO 140 Dose 1PRO 140 Dose 2PRO 140 Dose 3PRO 140 Dose 4
Started44444
Completed44444
Not completed00000

Outcome measures

PrimarySafety and Tolerability of PRO 140
Time frame:
60 days
Reported as:
Number · number of subjects reporting AEs
Safety and Tolerability of PRO 140
number of subjects reporting AEsPlaceboPRO 140 Dose 1PRO 140 Dose 2PRO 140 Dose 3PRO 140 Dose 4
Safety and Tolerability of PRO 14044043

Adverse events

Collected over Adverse event data was collected over an 18-month period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/4 (0%)4/4 (100%)
PRO 140 Dose 1—1/4 (25%)4/4 (100%)
PRO 140 Dose 2—0/4 (0%)0/4 (0%)
PRO 140 Dose 3—0/4 (0%)4/4 (100%)
PRO 140 Dose 4—0/4 (0%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventPlaceboPRO 140 Dose 1PRO 140 Dose 2PRO 140 Dose 3PRO 140 Dose 4
Myocardial infarctionCardiac disorders0/41/40/40/40/4
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlaceboPRO 140 Dose 1PRO 140 Dose 2PRO 140 Dose 3PRO 140 Dose 4
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders0/40/40/43/41/4
high creatine phosphokinase levelInvestigations2/40/40/40/42/4
Aspartate aminotransferase increasedInvestigations2/40/40/40/40/4
HeadacheNervous system disorders1/41/40/42/41/4
Fatal Myocardial infarctionCardiac disorders0/41/40/40/40/4
Abdominal pain upperGastrointestinal disorders0/40/40/41/40/4
Loose stoolsGastrointestinal disorders0/40/40/41/40/4
NauseaGastrointestinal disorders0/40/40/41/40/4
Joint sprainInjury, poisoning and procedural complications0/41/40/40/40/4
Alanine aminotransferase increasedInvestigations1/40/40/40/40/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboPRO 140 Dose 1PRO 140 Dose 2PRO 140 Dose 3PRO 140 Dose 4Total
<=18 years000000
Between 18 and 65 years4444420
>=65 years000000
Age, Continuous
Age, Continuous(years)PlaceboPRO 140 Dose 1PRO 140 Dose 2PRO 140 Dose 3PRO 140 Dose 4Total
Mean26 ± 734 ± 1330 ± 1222 ± 221 ± 227 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPRO 140 Dose 1PRO 140 Dose 2PRO 140 Dose 3PRO 140 Dose 4Total
Female000000
Male4444420
Region of Enrollment
Region of Enrollment(participants)PlaceboPRO 140 Dose 1PRO 140 Dose 2PRO 140 Dose 3PRO 140 Dose 4Total
United States4444420
08

Study locations

1 site
  • MDS Pharma Services
    Lincoln, Nebraska 68502, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Nov 2005 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2023, 17 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2005
First posted
May 11, 2005
Start
Apr 16, 2004
Primary completionActual
Nov 7, 2005
CompletionActual
Mar 31, 2008
Results first posted
Mar 14, 2023
Last update
Mar 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00110591
Lead sponsor
CytoDyn, Inc.
Responsible party
Sponsor
First posted
May 11, 2005
Start date
Apr 16, 2004
Primary completion
Nov 7, 2005
Completion
Mar 31, 2008
Results posted
Mar 14, 2023
Last update
Mar 14, 2023

Study contacts

William Olson, PhD
study chair · Vice President, Clinical Research, Progenics Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion